{
    "Clinical Trial ID": "NCT00290758",
    "Intervention": [
        "INTERVENTION 1: ",
        "  Arm A (Genistein)",
        "  Patients receive oral genistein once daily for up to 6 months.",
        "INTERVENTION 2: ",
        "  Arm B (Placebo)",
        "  Patients receive oral placebo once daily for up to 6 months."
    ],
    "Eligibility": [
        "Inclusion Criteria:",
        "  No known soy intolerance",
        "  At increased risk of developing breast cancer in >= 1 previously unaffected breast, as defined by any of the following:",
        "  Estimated 5-year risk of developing breast cancer using the Gail model, as defined by 1 of the following:",
        "  Gail score >= 1.66%",
        "  Gail score >= 0.1% for women age 20-29 years",
        "  Gail score >= 1.0% for women age 30-39 years",
        "  Estimated 5-year risk of developing breast cancer using the Claus model:",
        "  Claus score >= 1.66%",
        "  Claus score >= 0.1% for women age 20-29 years",
        "  Claus score >= 1.0% for women age 30-39 years",
        "  Prior diagnosis of unilateral in situ or invasive breast cancer OR history of atypical hyperplasia, BRCA 1 and/or BRCA 2 positivity",
        "  History of lobular carcinoma in situ",
        "  No evidence of breast cancer, as determined by a negative mammogram within the past 6 months and a history and physical",
        "  No previously diagnosed breast cancer unless all systemic therapy (including endocrine therapy) was completed at least 1 year ago",
        "  Pre- or postmenopausal",
        "  ECOG performance status 0-1",
        "  Hemoglobin > 10.0 g/dL",
        "  Platelet count > 100,000/mm^3",
        "  Absolute neutrophil count > 1,000/mm^3",
        "  Creatinine < 2.0 mg/dL",
        "  SGPT < 82 U/L",
        "  SGOT < 68 U/L",
        "  Bilirubin < 3 mg/dL* [Note: * Patients with a higher level of bilirubin due to a familial metabolism may be eligible at the discretion of the investigator]",
        "  Life expectancy > 2 years",
        "  Not pregnant or nursing",
        "  Negative pregnancy test",
        "  Fertile patients must use effective barrier contraception",
        "  Must be willing to keep a dietary diary",
        "  No venous thrombosis within the past year",
        "  No unrecognized or poorly controlled thyroid disease",
        "  No other cancer within the past 5 years except nonmelanomatous skin cancer or noninvasive cervical cancer",
        "  No other medical condition that, in the opinion of the investigator, would jeopardize either the patient or the integrity of the data obtained",
        "  None of the following for >= 2 weeks before the first random fine needle aspiration and during study participation:",
        "  Oral contraceptives",
        "  Soy supplements",
        "  High soy-containing foods",
        "  Fish oil supplements",
        "  Multivitamins",
        "  Vitamins C and E",
        "  Daily aspirin or nonsteroidal",
        "  Anti-inflammatory drugs",
        "  No other concurrent investigational agents",
        "  No concurrent warfarin or other blood thinners",
        "  Female patient",
        "Exclusion Criteria:",
        "  Women previously diagnosed with breast cancer will not be eligible unless all systemic therapy (including endocrine therapy) was completed at least one year previously",
        "  Currently pregnant, or planning to become pregnant during the study period",
        "  History of venous thrombosis within past year",
        "  Medical conditions, which, in the opinion of the investigators would jeopardize either the patient or the integrity of the data obtained",
        "  History of other cancer within the past five years, excluding non-melanomatous skin cancer, and non-invasive cervical cancer",
        "  Known soy intolerance",
        "  Unrecognized or uncontrolled thyroid disease, subjects may be on synthroid, but thyroid function must be in normal range or the patient's physician must document that the patient's thyroid is controlled.",
        "  Currently receiving any other investigational agents",
        "  Currently on coumadin, or other blood thinners",
        "  History of breast augmentation implants.",
        "  Rusults from patients who have <4000 epithelial cells in either the first or the second random Fine-needle aspiration (rFNA) will not be included in the study."
    ],
    "Results": [
        "Outcome Measurement: ",
        "  Change in Breast Epithelial Cell Proliferation as Measured by Ki-67 Labeling",
        "  Breast epithelial tissue samples are used to measure the expression of the cell proliferation marker Ki-67, by counting the percentage of positive MIB-1 immunostained cells, denoted the Ki-67 labeling index. Mean change in the Ki-67 labeling index is assessed from baseline to 6 month follow up.",
        "  Time frame: 6 months - baseline",
        "Results 1: ",
        "  Arm/Group Title: Arm A (Genistein)",
        "  Arm/Group Description: Patients receive oral genistein once daily for up to 6 months.",
        "  Overall Number of Participants Analyzed: 49",
        "  Mean (Standard Deviation)",
        "  Unit of Measure: Ki-67 labeling index  Postmenopausal with ER- Cancer: 4 participants",
        "  .325         (.343)",
        "  Postmenopausal with ER+ Cancer: 2 participants",
        "  -.418         (.191)",
        "  Postmenopausal Without Cancer: 14 participants",
        "  -.092         (.525)",
        "  Premonopausal with ER- Cancer: 2 participants",
        "  -.335         (.930)",
        "  Premenopausal with ER+ Cancer: 4 participants",
        "  -.387         (.806)",
        "  Premenopausal without cancer: 23 participants",
        "  1.171         (2.922)",
        "Results 2: ",
        "  Arm/Group Title: Arm B (Placebo)",
        "  Arm/Group Description: Patients receive oral placebo once daily for up to 6 months.",
        "  Overall Number of Participants Analyzed: 49",
        "  Mean (Standard Deviation)",
        "  Unit of Measure: Ki-67 labeling index  Postmenopausal with ER- Cancer: 2 participants",
        "  .289         (.541)",
        "  Postmenopausal with ER+ Cancer: 5 participants",
        "  -.461         (.458)",
        "  Postmenopausal Without Cancer: 15 participants",
        "  -.122         (.735)",
        "  Premonopausal with ER- Cancer: 2 participants",
        "  .873         (.786)",
        "  Premenopausal with ER+ Cancer: 4 participants",
        "  -.204         (1.329)",
        "  Premenopausal without cancer: 21 participants",
        "  0.557         (1.546)"
    ],
    "Adverse Events": [
        "Adverse Events 1:",
        "  Total: 6/62 (9.68%)",
        "  Musculoskeletal * 1/62 (1.61%)",
        "  Mood Alteration: Depression * 1/62 (1.61%)",
        "  renal - Other * 1/62 (1.61%)",
        "  Obstruction, GU: Uterus * 1/62 (1.61%)",
        "  Sexual * 0/62 (0.00%)",
        "  Pulmonary/Upper Respiratory: Dyspnea * 1/62 (1.61%)",
        "  Ulceration * 1/62 (1.61%)",
        "Adverse Events 2:",
        "  Total: 1/64 (1.56%)",
        "  Musculoskeletal * 0/64 (0.00%)",
        "  Mood Alteration: Depression * 0/64 (0.00%)",
        "  renal - Other * 0/64 (0.00%)",
        "  Obstruction, GU: Uterus * 0/64 (0.00%)",
        "  Sexual * 1/64 (1.56%)",
        "  Pulmonary/Upper Respiratory: Dyspnea * 0/64 (0.00%)",
        "  Ulceration * 0/64 (0.00%)"
    ]
}